J INTS BIO
- Country
- π°π·South Korea
- Ownership
- Private
- Established
- 2021-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.jintsbio.com
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
- Conditions
- EGFR Mutant Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- J Ints Bio
- Target Recruit Count
- 150
- Registration Number
- NCT05394831
- Locations
- πΊπΈ
Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, Orange, California, United States
π°π·Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
π°π·National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- J Ints Bio
- Registration Number
- NCT04526717
Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies
- Conditions
- Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- J Ints Bio
- Registration Number
- NCT04294875
News
J INTS BIO's Fourth-Generation EGFR-TKI JIN-A02 Shows Promising Anti-Tumor Activity in Resistant NSCLC Patients
J INTS BIO presented interim Phase 1/2 clinical trial results for JIN-A02, a fourth-generation EGFR-TKI designed to overcome resistance mutations that develop after third-generation EGFR-TKI treatment failure.
J INTS BIO's JIN-A02 Shows Promise in EGFR-TKI Resistant NSCLC
J INTS BIO presented interim Phase 1/2 data for JIN-A02, a 4th-generation EGFR-TKI, at the ENA Symposium, targeting resistant NSCLC.